Resolution of inflammation: what controls its onset?
An effective resolution program may be able to prevent the progression from non-resolving
acute inflammation to persistent chronic inflammation. It has now become evident that …
acute inflammation to persistent chronic inflammation. It has now become evident that …
Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice
S Bruscoli, M Febo, C Riccardi, G Migliorati - Frontiers in immunology, 2021 - frontiersin.org
Inflammatory bowel disease (IBD) comprises ulcerative colitis (UC) and Crohn's disease
(CD). IBD etiopathology is multifactorial and involves alteration of immune cells and chronic …
(CD). IBD etiopathology is multifactorial and involves alteration of immune cells and chronic …
More than suppression: glucocorticoid action on monocytes and macrophages
JM Ehrchen, J Roth, K Barczyk-Kahlert - Frontiers in immunology, 2019 - frontiersin.org
Uncontrolled inflammation is a leading cause of many clinically relevant diseases. Current
therapeutic strategies focus mainly on immunosuppression rather than on the mechanisms …
therapeutic strategies focus mainly on immunosuppression rather than on the mechanisms …
Glucocorticoids, sex hormones, and immunity
O Bereshchenko, S Bruscoli, C Riccardi - Frontiers in immunology, 2018 - frontiersin.org
Glucocorticoid hormones regulate essential body functions in mammals, control cell
metabolism, growth, differentiation, and apoptosis. Importantly, they are potent suppressors …
metabolism, growth, differentiation, and apoptosis. Importantly, they are potent suppressors …
Mediators of the resolution of the inflammatory response
The termination of inflammation is governed by endogenous molecules collectively referred
to as 'mediators of resolution'of inflammation. There is now strong evidence to suggest that …
to as 'mediators of resolution'of inflammation. There is now strong evidence to suggest that …
Resolution pharmacology: focus on pro-resolving annexin A1 and lipid mediators for therapeutic innovation in inflammation
M Perretti, J Dalli - Annual Review of Pharmacology and …, 2023 - annualreviews.org
Chronic diseases that affect our society are made more complex by comorbidities and are
poorly managed by the current pharmacology. While all present inflammatory …
poorly managed by the current pharmacology. While all present inflammatory …
From NSAIDs to glucocorticoids and beyond
A Sinniah, S Yazid, RJ Flower - Cells, 2021 - mdpi.com
Our interest in inflammation and its treatment stems from ancient times. Hippocrates used
willow bark to treat inflammation, and many centuries later, salicylic acid and its derivative …
willow bark to treat inflammation, and many centuries later, salicylic acid and its derivative …
[HTML][HTML] Resolving inflammation by TAM receptor activation
JP Vago, FA Amaral, FAJ van de Loo - Pharmacology & Therapeutics, 2021 - Elsevier
The control of inflammation is strictly regulated to ensure the adequate intensity and duration
of an inflammatory response, enabling the removal of the trigger factors and the restoration …
of an inflammatory response, enabling the removal of the trigger factors and the restoration …
GILZ as a mediator of the anti-inflammatory effects of glucocorticoids
S Ronchetti, G Migliorati, C Riccardi - Frontiers in endocrinology, 2015 - frontiersin.org
Glucocorticoid-induced leucine zipper (GILZ) is a dexamethasone-inducible gene that
mediates glucocorticoid (GC) actions in a variety of cell types, including many cells of …
mediates glucocorticoid (GC) actions in a variety of cell types, including many cells of …
Glucocorticoids and COVID-19
S Bruscoli, PG Puzzovio, M Zaimi, K Tiligada… - Pharmacological …, 2022 - Elsevier
Abstract Coronavirus Disease 19 (COVID-19) is associated with high morbidity and mortality
rates globally, representing the greatest health and economic challenge today. Several …
rates globally, representing the greatest health and economic challenge today. Several …